Biotech Values

[DewDiligence]

IDIX 2008-2009 Clinical Goals

[Updated with guidance from 1Q08 CC.]


HIV / IDX899

2Q08: Complete 200mg arm of 7-day monotherapy study. (Data from the 800mg cohort were reported on 2/6/08 [#msg-26606685]; an update on the 400mg arm was given on the 1Q08 CC [#msg-28894709].)

Jun 08: Present monotherapy results at ESCMID conference (#msg-28927959).

3Q08: Start phase-2 combination study: IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients.

End 2008: Partner IDX899 program depending on results of phase-2 combo study (#msg-28959639).

Feb 09: Present data from phase-2 combo study at CROI conference.


HCV

Mid 2008: File IND/CTA for IDX184.

End 2008: Report initial data for IDX184 in HCV patients. (The plan is to skip testing in healthy volunteers and proceed directly to patients.)

1H09: File IND/CTA for first HCV protease inhibitor.